FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
05/01/2025
Voltar para busca
Dado oficial do USPTO
TME PHARMA
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
30
Atualização mais recente
05/01/2025
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
1, 5, 42, 44
Data de depósito
03/11/2022
Data de registro
25/06/2024
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
25/06/2024
Última transação
05/01/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
3
Tipo de titular
03
Localização do titular
DE
Examinador
BULLOFF, TOBY
Localização atual
FILE REPOSITORY (FRANCONIA)
Descrição da marca
The mark consists of the stylized blue wording 'TME pharma' stacked to the left of a design comprised of a light blue circle containing transparent lines partially surrounded by a light green and blue curved line.
Titulares e representantes
Titulares
TME Pharma AG
Representantes
Ursula B. Day law firm of Ursula B. Day
Classificação técnica
Classes Nice
Classe 1Classe 5Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Chemicals for use in industry and science, in particular compounds of nucleic acids and derivatives thereof and l-nucleotides and proteins and peptides and derivatives thereof, all for use in the production and development of pharmaceuticals, veterinary and biotechnological products;
Classe 5
Medicines, medical preparations and medicines for animals, namely, for treating cancer and ophthalmological indications, diagnostic agents for pharmaceutical use; pharmaceuticals and natural remedies, namely, for treating cancer and ophthalmological indications; pharmaceutical compositions, namely, for treating cancer and ophthalmological indications; pharmaceutical preparations, namely, for treating cancer and ophthalmological indications;
Classe 42
Science and technology services, namely, scientific analysis in the field of biotechnology, therapeutics and research and planning services relating to development of pharmaceuticals; medical and pharmacological research services; pharmaceutical research; computer software design; design of databases, design of online databases; computer programming, namely, updating, design and rental of computer software for managing medical patient data, medical teaching and interactive medical simulations; providing online, non-downloadable computer programs and data networks for managing medical patient data, medical teaching and interactive medical simulations; scientific and technological services, namely, scientific analysis in the field of biotechnology, therapeutics and research and design relating thereto in the field of genetic engineering; scientific research for medical purposes and for biochemical use, scientific contract research; research and development of processes, syntheses and devices for the medical sector and research in the fields of chemistry, biology, biophysics, medicine, biochemistry, genetics, genetic engineering, bacteriology; scientific experiments and analyses; surveying; chemistry services, namely, laboratory research in the field of chemistry, biotechnology, medicine; chemical laboratories; medical laboratory services
Classe 44
Medical services in the field of medicine; medical and clinical examinations; pharmaceutical advice;
Publicações
Histórico de despachos e eventos da marca no USPTO.
30 publicações encontradas
FICS
FINAL DISPOSITION NOTICE SENT TO IB
12/12/2024
FIMP
FINAL DISPOSITION PROCESSED
11/12/2024
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
25/09/2024
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
25/06/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
25/06/2024
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
10/06/2024
GPNX
NOTIFICATION PROCESSED BY IB
15/04/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
09/04/2024
PUBO
PUBLISHED FOR OPPOSITION
09/04/2024
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
27/03/2024
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
27/03/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
20/03/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
29/02/2024
XAEC
EXAMINER'S AMENDMENT ENTERED
29/02/2024
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
29/02/2024
GNEA
EXAMINERS AMENDMENT E-MAILED
29/02/2024
CNEA
EXAMINERS AMENDMENT -WRITTEN
29/02/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
28/02/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
28/02/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
28/02/2024
RFNP
REFUSAL PROCESSED BY IB
11/10/2023
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
14/09/2023
RFRR
REFUSAL PROCESSED BY MPU
13/09/2023
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
23/08/2023
CNRT
NON-FINAL ACTION WRITTEN
22/08/2023
DOCK
ASSIGNED TO EXAMINER
18/08/2023
MAFR
APPLICATION FILING RECEIPT MAILED
17/01/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
13/01/2023
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
12/01/2023
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace TME PHARMA ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.